1 active not recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Breast: new trials by email Literature Review of Breast trials Research Report on Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. Olaparib, MEDI4736, Bevacizumab - Ovarian, Breast | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 264 | 2016-03-17 | 2026-07-14 |
Breast Neoplasms (1) · Ovarian Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
Adnexal Diseases (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1)
Bevacizumab (1) · durvalumab (1) · olaparib (1)
AstraZeneca (1)
France (1) · Israel (1) · Netherlands (1) · South Korea (1) · Switzerland (1) · United Kingdom (1) · United States (1)
PMID 32771088, PMID 35756843, PMID 37939124
2015 (1)